Research programme: biodefence antibodies - NanotherapeuticsAlternative Names: Anti-H1N1 (swine flu) antibodies - XOMA; Anti-H5N1 (bird flu) antibodies - XOMA; Anti-influenza A antibodies - XOMA; Anti-severe acute respiratory syndrome (SARS) antibodies - XOMA; Antibotulinum toxin antibodies - XOMA; Antibotulism antibodies - XOMA; Biodefense antibodies - XOMA; F10 antibody - XOMA; NTM 1634; XOMA 3EB
Latest Information Update: 20 Feb 2017
At a glance
- Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
- Developer XOMA
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype
- Research Severe acute respiratory syndrome
Most Recent Events
- 20 Feb 2017 Nanotherapeutics plans a phase I trial for NTM 1634 in valunteers in USA (NCT03046550)
- 05 Nov 2015 Nanotherapeutics acquires biodefence antibodies programme from XOMA
- 07 Oct 2011 Preclinical development is ongoing for Botulism, Influenza A virus and Severe acute respiratory syndrome in the US.